Tirzepatide is among a wave of new weight loss therapies poised to hit the market that are making greater amounts of weight loss possible.
Source
Eli Lilly obesity drug delivers 20% weight loss, bolstering investment case for new therapies
U.S. surgeon general calls for cancer risk warnings on alcohol labels
A customer drinks a glass of beer at the Saxton Pub in Austin, Texas, April 5, 2023. Brandon Bell | Getty Images The U.S. surgeon general issued a new advisory warning Friday about the link between alcohol consumption and increased cancer risk, and pushed for policy changes to help reduce the number of alcohol-related cancers. […]
Read MoreThese innovative biotech stocks have a good chance of breaking out in 2025
Trends may be shifting in favor of biotech stocks in 2025 after several years of poor performance, but it would still be wise to place your bets carefully on some of the most innovative names. “We’re still optimistic on the outlook for biotech,” said Stacey Sears, senior vice president and portfolio manager at Emerald Advisors, […]
Read MoreDanaher had a disappointing 2024. Its path to success next year goes through Wall Street
Life sciences firm Danaher has certainly not been an easy stock to own this year. A wave of startups going public on Wall Street would go a long ways toward changing that. Year-to-date performance: down 0.1% Forward price-to-earnings multiple: 27.8 versus a five-year average of 28.8 Our rating: Buy-equivalent 1 Our price target: $305 a […]
Read More